Traditional drug discovery methods are inefficient and expensive – approximately 90% of all drugs in clinical trials ultimately fail to get approved and the total investment needed to develop each approved medicine exceeds $2 billion. This inefficiency occurs because biology is extraordinarily complex, and our industry has historically lacked the tools to understand how it functions. At Recursion, we’re harnessing the convergence of multiple breakthrough technologies that allow our scientists to explore uncharted areas of biology and unravel its complexity to navigate the path to better treatments. We have built a massive proprietary biological and chemical database that predicts trillions of relationships across biology and chemistry, many of which are not known in scientific literature. Our approach generates novel insights, broadens the scope of potential medicines, and truly industrializes drug discovery – increasing the scale, speed and efficiency of each step of the process. We believe our technology and approach has the potential to not only radically improve the lives of patients, but also change the landscape of drug discovery and development forever.
